Regulus Therapeutics Inc. reported developments as a biopharmaceutical company focused on discovering and developing medicines that target microRNAs. Company news centered on farabursen (RGLS8429), its oligonucleotide drug candidate for autosomal dominant polycystic kidney disease, including Phase 1b multiple-ascending-dose clinical data, biomarker measures such as PC1, PC2 and htTKV, and regulatory interactions with the FDA.
Regulus updates also included operating and financial results, management participation in healthcare conferences, material agreements, shareholder voting matters, governance items and capital-structure disclosures. Later company disclosures reflected corporate-transaction activity that changed the public-company status of RGLS.
Regulus Therapeutics Inc. will participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast Series, with CEO Jay Hagan and President Preston Klassen, M.D. The event, hosted by Whitney Ijem on May 1, 2024, at 1:00 p.m. ET, will be live and available for replay on the company's investor relations website for 90 days.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.